
    
      This study is a multicenter, randomized, double-blind, dose-ranging study to evaluate the
      efficacy and safety of different doses of TG-1000 compared with placebo in adult patients
      with acute uncomplicated influenza virus infection.

      Approximately 200 patients will be randomly assigned to 1 of 4 treatments groups in a ratio
      of 1:1:1:1 to receive study treatment orally: "40 mg TG-1000", "80 mg TG-1000", "40mg+40mg
      TG-1000" or "placebo".
    
  